

The future of lung health

4DM

18.2 26.5 11

ica

4DMedical Limited (ASX:4DX) Annual General Meeting 20 November 2024

4DMedical Limited ABN 31 161 684 831

Disclaimer

This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (**Company** or **4DMedical**). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (**Group**) and their activities current as of 20 November 2024 unless otherwise stated and the information remains subject to change without notice. This presentation contains general background information and does not purport to be complete. No attempt has been made to independently verify the information contained in this presentation.

Not an offer or financial product advice

The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly, any securities to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities.

This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian *Corporations Act 2001* (Cth) (**Corporations Act**) or other offer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase securities and does not include any application form for securities. This presentation does not constitute an advertisement for an offer or proposed offer of securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation.

The distribution of this presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this presentation may not be distributed or released in the United States. The securities in the Company (**Securities**) have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (**U.S. Securities Act**), or the securities laws of any state or other jurisdiction of the United States. Accordingly, the Securities may not be offered or sold, directly or indirectly, in the United States, unless they have been registered under the U.S. Securities Act (which the Company has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable securities laws of any state or other jurisdiction of the United States.

4DMedical

Overview

ca

Tidal Volume 0.37 L

18.2 26.5 11.0

4DMedical



- 1. Opening & introductions
- 2. Chair's address
- 3. CEO's address
- 4. Procedural matters
- 5. Formal business
- 6. Closing remarks

Board of Directors – significant medical and commercial sector experience



LIL BIANCHI Non-Executive Chair Chair, Audit & Risk Committee

Experienced contributor of business transformations for US listed technology companies with a beneficial technology product expertise in AI and SaaS offerings.



Dr ANDREAS FOURAS PhD **Managing Director and CEO**

Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies.



Dr ROBERT A. FIGLIN MD Non-Executive Director

Globally recognised leader in genitourinary and thoracic oncology, as well as Editor of the Kidney Cancer Journal and Spielberg Family Chair in Hematology/Oncology at Cedars Sinai.

Key Advisors



Dr DAVID J. SHULKIN MD Key Advisor

Highly respected physician and health care executive, Dr Shulkin was previously the Secretary of the United States Department of Veterans Affairs (VA). As Secretary of the VA, Dr Shulkin oversaw the US government's second largest agency, with over 350,000 employees and 1,700 facilities, serving over 9 million Veterans.



Dr GERALDINE McGINTY MD Non-Executive Director

Internationally recognised expert in health care strategy and imaging economics, and prominent advocate for patientcentered care. A Professor of Radiology and Population Health Sciences at Weill Cornell Medicine in New York City, she serves as Senior Associate Dean for Clinical Affairs.





JULIAN SUTTON **Non-Executive Director**

Chartered Financial Analyst who began his career as an actuarial analyst in Melbourne before moving into funds management with Schroders and Credit Suisse in London.



JOHN LIVINGSTON **Executive Director**

Founding partner of ASX listed Integral Diagnostics (ASX:IDT) and an industry leader in the implementation of PACS and RIS in radiological settings.

Dr SAM HUPERT MBBS

Advisory Board Member

Co-founder and Chief Executive Officer of Pro Medicus Ltd (ASX:PME) which develops and markets health imaging software primarily for radiologists in the U.S., Europe and Australia.



Board Member and Past President of the Thoracic Society of Australia and New Zealand; currently Dean of the School of Health Sciences at the University of Melbourne, and a former Head of Physiology Services at the Alfred Hospital.



Chair's address



LIL BIANCHI Non-Executive Chair

Experienced contributor of business transformations for US listed technology companies with a beneficial technology product expertise in AI and SaaS offerings.

0.37 L

18.2 26.5 11.0



FY24 Financial Summary

- 4DMedical reported a net cash balance of
 \$30.6 million at 30 June 2024, with zero debt.
- Total operating revenue of \$3.8 million, up 422% on
 pcp, with total income of \$14.8 million including
 \$11.0 in other income.
- Total net operating expenditure \$30.3 million, up 2.5%, reflecting a reduction in R&D and clinical trial expenditure offset by increased investment in commercialisation activities.

\$30.6m Cash reserves (zero debt)

\$30.3m

Net operating

expenditure

\$3.8m Operating Revenue +422% vs FY23

\$14.8m Total Income (includes \$11.0m of grant income and R&D tax credits)

(3.4%) Reduction in underlying 4DMedical operating expenses **145** Employees globally

4DMedical

CEO's address



Dr ANDREAS FOURAS PhD Managing Director

Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies.

4DMedical


R

0.37 L

18.2 26.5 11.0

4DMedical

Global respiratory diagnostic market valued at US\$31.4 billion per annum



378 million global respiratory diagnostics tests performed annually¹

Current lung diagnostics are failing us

Lung health screening (COPD, silicosis, black lung, lung cancer)



- COPD 4th largest cause of mortality in world¹
- Silicosis 600,000 Australian workers exposed to silica dust per annum

Unexplained dyspnoea (shortness of breath)




- \$12.2bn cost of breathlessness in Australia²
- 9.5% of Australians have clinically relevant breathlessness

Burn Pits & DRRD (Deployment-related Respiratory Disease)




- >6million service personnel exposed to airborne toxic hazards³
- No standard diagnostics detecting presence or absence of DRRD

Comprehensive chest diagnostics product suite



A complete lung health solution



*FDA Cleared, ** CE Approved, ***FDA clearance in progress, ^pending submission

Solving the clinical conundrum for doctors across multiple care areas

Clinical Conundrum in Lung Assessment

A mismatch between clinical tests and imaging often occurs, whereby anatomic findings can overlap, lag, or precede clinical symptoms.

Need structural and functional data/information to make a better, informed clinical decision.

Not solved by historical **standard** of care testing (Spirometry, X-ray, CT scans)

Clinical Tools Needed to Solve the Conundrum

Functional lung analysis providing visual qualitative and quantitative assessment of ventilation



Structural lung analysis providing visual qualitative and quantitative assessment of lung anatomy



Applications for Technologies in Clinical Practice

Unexplained dyspnoea Example technology A complex clinical presentation Is it Lung related? Is it Cardiac related?

Restrictive diseases

XV LVAS[®] LDA

CT LVAS[™]

CAC

PAH

DRRD / CB Deployment-related respiratory disease/ LTA Constrictive bronchiolitis | ILD Interstitial Lung Disease | IQ-UIP **IPF** Idiopathic pulmonary fibrosis | **Dust Exposures** — Silicosis, asbestosis, pneumoconiosis

Obstructive diseases

Fibrosis

COPD Chronic Obstructive Pulmonary Disease— Emphysema, Chronic Bronchitis | Asthma | CF Cystic

Is it other causes or psychosomatic?


LDA **CT LVAS**[™] XV LVAS[®]

Intervention and pharmaceutical

Lung Reduction therapies | Disease progression / regression | Compliance

LDA IQ-UIP CT: VQ **XV LVAS®** LTA

FY24 achievements – building the foundations



Commercialisation strategy



Philips overview

		les (2023), ~70% in #1	althcare – portfolio or #2 positions; ~40% Europe, 9% other matu	sales recurring reven		
Diagnosis & treatment:Connected care:~50% of sales (2023 full year)~30% of sales (2023 full year)			ear)	Personal health: ~20% of sales (2023 full year)		
Diagnostic imaging Top 3 player	Ultrasound #1 Cardiac	Image Guided Therapy #1 Systems & devices	Enterprise Monitoring Sleep & Respiratory Informatics Care #2 Oral #1 Imaging PACS & #1 in Hospital #1 Male			Personal Health #2 Oral Healthcare #1 Male Grooming #2 Infant Feeding
Systems, smart devices, software and services, powered by AI-enabled informatics Supporting precision diagnosis and minimally invasive treatment in a growing number of therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology			solutions fueled by ad Connecting patients	pased and in-hospital mo vanced interoperability a and caregivers across ca perational and therapeut	nd patient data insights re settings, delivering	Broad range of consumer solutions to support people in proactively managing their health and wellbeing


Market-leading capabilities integrating platforms, informatics, and services

1. Source: Philips website: <u>https://www.philips.com/a-w/about</u>

2. Source: Philips Investor Centre: <u>https://www.philips.com/a-w/about/investor-relations.html</u>



Philips reseller agreement



2. Figures adapted from Frost and Sullivan Report 2020 USD \$31.3 billion global spend annually (table)

Procedural matters

4 4 D Medicaľ

Items of business

Item 1: Financial Report, Directors' Report and Auditors Report

- **Item 2:** Remuneration Report
- **Item 3:** Re-election of Director, Dr Robert A. Figlin
- **Item 4:** Issue of securities to Directors
- Item 5: Issue of securities to Directors in lieu of base directors' fees Ms Lil Bianchi and Dr Geraldine McGinty
- **Item 6:** Grant of Options to the Managing Director and CEO
- **Item 7:** Approval of 10% placement capacity

Item 8: Ratification of prior issue of shares

Item 1: Financial Report, Directors' Report and Auditors Report

To receive and consider the Financial Report of the Company and its controlled entities and the Reports of the Directors and Auditor for the year ended 30 June 2024.

Item 2: Remuneration Report

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

"That the Remuneration Report, as contained in the Directors' Report for the year ended 30 June 2024, is adopted."

In Favour	Against	Proxy Discretion	Abstain
15,628,689	8,141,784	3,024,919	981,043
58.33%	30.38%	11.29%	

- The Board unanimously recommends that Shareholders vote in favour of Item 2.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Item 3: Re-election of Director, Dr Robert A. Figlin

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

"That, for the purposes of clause 13.3(b) of the Constitution, ASX Listing Rule 14.4, and for all other purposes, Dr Robert A. Figlin, a non-executive director appointed on 9 December 2016 retires in accordance with clause 13.3(a) of the Constitution, and being eligible, is re-elected as a director."

In Favour	Against	Proxy Discretion	Abstain
89,116,834	289,674	3,157,374	128,082
96.28%	0.31%	3.41%	

- The Board (other than Dr Figlin) unanimously recommends that Shareholders vote in favour of Item 3.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.

Items 4A to 4E: Approval for the proposed issue of securities to Directors

Item ₄A

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

"That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 91,257 Options to **Ms Lil Bianchi** (or her nominee) under the Incentive Plan on the terms and conditions described in the Explanatory Statement."

Item 4B

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

"That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 60,147 Options to **Mr John Livingston** (or his nominee) under the Incentive Plan on the terms and conditions described in the Explanatory Statement."

Item ₄C

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

"That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 60,147 Options to **Mr Julian Sutton** (or his nominee) under the Incentive Plan on the terms and conditions described in the Explanatory Statement."

In Favour	Against	Proxy Discretion	Abstain
18,114,801	6,287,208	3,013,691	360,715
66.07%	22.93%	10.99%	

In Favour	Against	Proxy Discretion	Abstain
15,614,292	8,798,464	3,008,691	354,968
56.94%	32.09%	10.97%	

In Favour	Against	Proxy Discretion	Abstain
15,541,685	8,855,324	3,018,691	360,715
56.69%	32.30%	11.01%	

Items 4A to 4E: Approval for the proposed issue of securities to Directors

Item 4D

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

"That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 60,147 Restricted Stock Units to **Dr Robert A. Figlin** (or his nominee) under the Incentive Plan on the terms and conditions described in the Explanatory Statement."

Item ₄E

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

"That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 60,147 Restricted Stock Units to **Dr Geraldine McGinty** (or her nominee) under the Incentive Plan on the terms and conditions described in the Explanatory Statement."

- The Chair of the meeting intends to vote undirected proxies in favour of Items 4A to 4E.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

In Favour	Against	Proxy Discretion	Abstain
18,091,940	6,295,629	3,018,691	370,155
66.01%	22.97%	11.01%	

In Favour	Against	Proxy Discretion	Abstain
20,467,840	3,879,729	3,018,691	410,155
74.79%	14.18%	11.03%	

Items 5A and 5B: Approval for the proposed issue of securities to Directors in lieu of base directors' fees

Item 5A

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

"That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 105,649 Options to **Ms Lil Bianchi** (or her nominee) in lieu of base directors' fees under the Incentive Plan on the terms and conditions described in the Explanatory Statement."

Item 5B

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

"That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 77,640 Restricted Stock Units to **Dr Geraldine McGinty** (or her nominee) in lieu of base directors' fees under the Incentive Plan on the terms and conditions described in the Explanatory Statement."

- The Board (other than Ms Bianchi and Dr McGinty) unanimously recommends that Shareholders vote in favour of Items 5A and 5B.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

In Favour	Against	Proxy Discretion	Abstain
22,101,568	2,225,824	3,104,109	344,914
80.57%	8.11%	11.32%	

In Favour	Against	Proxy Discretion	Abstain
22,123,936	2,178,737	3,033,410	440,332
80.93%	7.97%	11.10%	

Item 6: Grant of Options to the Managing Director and CEO

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

"That, for the purposes of ASX Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purposes, Shareholders approve the proposed grant of up to 775,339 Options, and potential termination benefits, to Managing Director and CEO, Dr Andreas Fouras, under the Incentive Plan and on the terms described in the Explanatory Statement."

In Favour	Against	Proxy Discretion	Abstain
16,940,616	7,495,055	3,023,663	317,081
61.69%	27.30%	11.01%	

- The Board (other than Dr Fouras) unanimously recommends that Shareholders vote in favour of Item 6.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Item 7: Approval of 10% Placement Facility

To consider, and if thought fit, to pass, the following as a **special** resolution:

"That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the issue of Equity Securities up to 10% of the fully paid ordinary issued capital of the Company (at the time of issued) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions set out in the Explanatory Statement."

In Favour	Against	Proxy Discretion	Abstain
79,963,161	9,288,824	3,137,548	302,431
86.55%	10.05%	3.40%	

- The Board unanimously recommends that Shareholders vote in favour of Item 7.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Item 8: Ratification of prior issue of Shares

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

"That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 19,000,000 Shares to Alpha Investment Partners Pty Ltd on the terms and conditions set out in the Explanatory Statement."

In Favour	Against	Proxy Discretion	Abstain
88,527,154	643,831	3,147,548	373,431
95.89%	0.70%	3.41%	

- The Board unanimously recommends that Shareholders vote in favour of Item 8.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.





ca

0.37 L

18.2 26.5 11.0

4DMedical Limited (ASX:4DX) Annual General Meeting 20 November 2024

Copyright © 4DMedical Limited 2024 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia

www.4dmedical.com

ABN 31 161 684 831

